NervGen Pharma (NGEN) Competitors

$2.08 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.09 +0.01 (+0.67%)

As of 05/22/2026 07:58 PM Eastern

NGEN vs. COLL, XERS, MRVI, CVAC, and AKTS

Should you buy NervGen Pharma stock or one of its competitors? MarketBeat compares NervGen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NervGen Pharma include Collegium Pharmaceutical (COLL), Xeris Biopharma (XERS), Maravai LifeSciences (MRVI), CureVac (CVAC), and Aktis Oncology (AKTS). These companies are all part of the "pharmaceutical products" industry.

How does NervGen Pharma compare to Collegium Pharmaceutical?

NervGen Pharma (NASDAQ:NGEN) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

NervGen Pharma currently has a consensus target price of $18.00, suggesting a potential upside of 765.38%. Collegium Pharmaceutical has a consensus target price of $57.50, suggesting a potential upside of 68.77%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Collegium Pharmaceutical has higher revenue and earnings than NervGen Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.70

In the previous week, NervGen Pharma had 10 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 12 mentions for NervGen Pharma and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.65 beat NervGen Pharma's score of 0.32 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has a net margin of 9.41% compared to NervGen Pharma's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Summary

Collegium Pharmaceutical beats NervGen Pharma on 6 of the 10 factors compared between the two stocks.

How does NervGen Pharma compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Xeris Biopharma has a net margin of 3.81% compared to NervGen Pharma's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
NervGen Pharma	N/A	N/A	N/A

Xeris Biopharma presently has a consensus price target of $10.80, indicating a potential upside of 74.47%. NervGen Pharma has a consensus price target of $18.00, indicating a potential upside of 765.38%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Xeris Biopharma has higher revenue and earnings than NervGen Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.66	$550K	$0.06	103.17
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, NervGen Pharma had 10 more articles in the media than Xeris Biopharma. MarketBeat recorded 12 mentions for NervGen Pharma and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.84 beat NervGen Pharma's score of 0.32 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.8% of Xeris Biopharma shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by company insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Xeris Biopharma beats NervGen Pharma on 8 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Maravai LifeSciences presently has a consensus target price of $5.50, indicating a potential upside of 25.00%. NervGen Pharma has a consensus target price of $18.00, indicating a potential upside of 765.38%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

In the previous week, NervGen Pharma had 11 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for NervGen Pharma and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.64 beat NervGen Pharma's score of 0.32 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

NervGen Pharma has lower revenue, but higher earnings than Maravai LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	6.12	-$130.77M	-$0.71	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

NervGen Pharma has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. NervGen Pharma's return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
NervGen Pharma	N/A	N/A	N/A

Summary

NervGen Pharma beats Maravai LifeSciences on 8 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to CureVac?

NervGen Pharma (NASDAQ:NGEN) and CureVac (NASDAQ:CVAC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

CureVac has higher revenue and earnings than NervGen Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

17.3% of CureVac shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, NervGen Pharma had 12 more articles in the media than CureVac. MarketBeat recorded 12 mentions for NervGen Pharma and 0 mentions for CureVac. NervGen Pharma's average media sentiment score of 0.32 beat CureVac's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
NervGen Pharma	Neutral
CureVac	Neutral

CureVac has a net margin of 199.92% compared to NervGen Pharma's net margin of 0.00%. NervGen Pharma's return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
CureVac	199.92%	-23.03%	-19.09%

NervGen Pharma presently has a consensus price target of $18.00, indicating a potential upside of 765.38%. CureVac has a consensus price target of $6.83, indicating a potential upside of 46.64%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe NervGen Pharma is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

NervGen Pharma beats CureVac on 8 of the 11 factors compared between the two stocks.

How does NervGen Pharma compare to Aktis Oncology?

NervGen Pharma (NASDAQ:NGEN) and Aktis Oncology (NASDAQ:AKTS) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, NervGen Pharma had 6 more articles in the media than Aktis Oncology. MarketBeat recorded 12 mentions for NervGen Pharma and 6 mentions for Aktis Oncology. NervGen Pharma's average media sentiment score of 0.32 beat Aktis Oncology's score of -0.62 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Negative

28.8% of Aktis Oncology shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by company insiders. Comparatively, 3.3% of Aktis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NervGen Pharma presently has a consensus target price of $18.00, indicating a potential upside of 765.38%. Aktis Oncology has a consensus target price of $32.00, indicating a potential upside of 57.33%. Given NervGen Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe NervGen Pharma is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Aktis Oncology	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
Aktis Oncology	$6.50M	167.10	N/A	N/A	N/A

Summary

NervGen Pharma beats Aktis Oncology on 6 of the 9 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$167.71M	$2.95B	$4.26B	$12.34B
Dividend Yield	N/A	15.26%	5.93%	5.28%
P/E Ratio	N/A	13.06	21.90	25.65
Price / Sales	N/A	1,857.06	180.55	86.28
Price / Cash	N/A	27.64	55.68	56.67
Price / Book	N/A	6.13	34.85	7.14
Net Income	N/A	-$42.06M	$112.32M	$335.98M
7 Day Performance	-42.86%	0.99%	2.55%	3.56%
1 Month Performance	N/A	1.57%	3.54%	2.54%
1 Year Performance	N/A	18.73%	15.79%	35.05%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	3.721 of 5 stars	$2.08 flat	$18.00 +765.4%	N/A	$167.71M	N/A	N/A	N/A	Gap Up High Trading Volume
COLL Collegium Pharmaceutical	2.964 of 5 stars	$33.78 flat	$57.50 +70.2%	+18.1%	$1.10B	$780.57M	16.56	210	Gap Up
XERS Xeris Biopharma	2.9835 of 5 stars	$6.24 flat	$10.80 +73.1%	+28.2%	$1.08B	$291.85M	104.00	290	Positive News
MRVI Maravai LifeSciences	3.0769 of 5 stars	$4.15 flat	$5.50 +32.5%	+98.2%	$1.07B	$185.74M	N/A	610	Positive News Analyst Upgrade
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. COLL, XERS, MRVI, CVAC, and AKTS

How does NervGen Pharma compare to Collegium Pharmaceutical?

Summary

How does NervGen Pharma compare to Xeris Biopharma?

Summary

How does NervGen Pharma compare to Maravai LifeSciences?

Summary

How does NervGen Pharma compare to CureVac?

Summary

How does NervGen Pharma compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. COLL, XERS, MRVI, CVAC, and AKTS

How does NervGen Pharma compare to Collegium Pharmaceutical?

Do analysts recommend NGEN or COLL?

Which has better earnings & valuation, NGEN or COLL?

Does the media refer more to NGEN or COLL?

Is NGEN or COLL more profitable?

Summary

How does NervGen Pharma compare to Xeris Biopharma?

Is XERS or NGEN more profitable?

Do analysts prefer XERS or NGEN?

Which has preferable earnings & valuation, XERS or NGEN?

Does the media prefer XERS or NGEN?

Do insiders & institutionals hold more shares of XERS or NGEN?

Summary

How does NervGen Pharma compare to Maravai LifeSciences?

Do institutionals and insiders believe in MRVI or NGEN?

Do analysts recommend MRVI or NGEN?

Does the media prefer MRVI or NGEN?

Which has better valuation and earnings, MRVI or NGEN?

Is MRVI or NGEN more profitable?

Summary

How does NervGen Pharma compare to CureVac?

Which has preferable valuation and earnings, NGEN or CVAC?

Do insiders and institutionals believe in NGEN or CVAC?

Does the media prefer NGEN or CVAC?

Is NGEN or CVAC more profitable?

Do analysts rate NGEN or CVAC?

Summary

How does NervGen Pharma compare to Aktis Oncology?

Does the media refer more to NGEN or AKTS?

Do insiders & institutionals believe in NGEN or AKTS?

Do analysts recommend NGEN or AKTS?

Is NGEN or AKTS more profitable?

Which has preferable earnings and valuation, NGEN or AKTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools